MESTP4: A Potential Drug Target and Biomarker (G131572)

Target Name: MESTP4

NCBI ID: G131572

MESTP4

Other Name(s): mesoderm specific transcript pseudogene 4 | Mesoderm specific transcript pseudogene 4

MESTP4: A Potential Drug Target and Biomarker

Introduction

Mesoderm specific transcript pseudogene 4 (MESTP4) is a gene that has been identified in various organisms, including humans. It is a member of the MESTP gene family, which is characterized by the presence of a specific transcription factor that binds to its promoter region . MESTP4 is expressed in various tissues and organs, including brain, heart, and muscle. Its function and regulation are not well understood, but it is considered as a potential drug target and biomarker.

Potential Drug Target

MESTP4 has been identified as a potential drug target due to its involvement in various cellular processes that are relevant to human health. One of the key functions of MESTP4 is its role in cell signaling, which is critical for the development and maintenance of tissues and organs . MESTP4 has been shown to be involved in the regulation of cell proliferation, differentiation, and survival.

In addition, MESTP4 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that MESTP4 is expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally , MESTP4 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important for the development of cancer, as the growth of new blood vessels can provide a source of oxygen and nutrients to the tumor.

Potential Biomarkers

MESTP4 has also been identified as a potential biomarker for various diseases, including cancer. The expression of MESTP4 has been shown to be associated with the development and progression of cancer, as well as the response to various treatments. For example, studies have shown that MESTP4 is downregulated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, MESTP4 has been shown to be involved in the regulation of cell cycle progression, which is critical for the development and progression of cancer.

MESTP4 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells die. This is important for the regulation of cell growth and the development of cancer. Additionally, MESTP4 has been shown to be involved in the regulation of inflammation, which is important for the development and progression of various diseases, including cancer.

Conclusion

MESTP4 is a gene that has been identified in various organisms, including humans. Its function and regulation are not well understood, but it is considered as a potential drug target and biomarker. The potential drug target of MESTP4 is its involvement in cell signaling, cell proliferation, differentiation, and survival, as well as its role in the development and progression of various diseases, including cancer. Additionally, MESTP4 has also been shown to be involved in the regulation of angiogenesis, cell cycle progression, apoptosis, and inflammation. Further studies are needed to fully understand its function and potential as a drug target and biomarker.

Protein Name: Mesoderm Specific Transcript Pseudogene 4

The "MESTP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MESTP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets